Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Pediatric Patients Undergoing Intensive Chemotherapy for Malignant Solid Tumors
NCT04485416Phase 1Terminated
- Sponsor
- University of California, Davis
- Start
- Jul 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eltrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by University of California, Davis. Primary endpoint: Safety and tolerability assessed by CTCAE v5.0. Started Jul 2021; status: terminated.
02
Drugs
eltrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT04485416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485416.